-0.40 | -5.88%
| Price and Volume | |
|---|---|
| Recent Price | 6.80 |
| 52 Week High | 6.88 |
| 52 Week Low | 2.40 |
| Avg. Daily Vol. (Mil) | 0.47 |
| Beta (3 year) | 1.81 |
| Share Related Items | |
| Mkt Cap (Mil) | 425.81 |
| Shares Out (Mil) | 62.62 |
| Float (Mil) | 50.72 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 1.80 |
| Current Ratio | 2.00 |
| LT Debt/ Equity | 0.17 |
| Total Debt / Equity | 0.17 |
| Valuation Ratios | |
| Price Earnings | 75.60 |
| Price/Sales | 3.00 |
| Price/Book | 7.47 |
| Price/Cash Flow | 44.10 |
| Per Share Data | |
| Earnings | 0.09 |
| Sales | 2.27 |
| Book Value | 0.91 |
| Cash Flow | 0.15 |
| Business Summary | |
|---|---|
| Santarus, Inc. is a specialty pharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by gastroenterologists and other targeted physicians. | |
| General Information | |
| 3721 Valley Centre Drive
Suite 400 San Diego, CA 92130 |
|
| www.santarus.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 237 | |
| CEO: Gerald T. Proehl | |
| Short Interest | |
| Current Month (Mil) | 2.73 |
| Previous Month (Mil) | 2.75 |
| Short Interest Ratio (Days) | 7.00 |
| Management Effectiveness | |
| Return on Equity | 10.20 |
| Return on Assets | 4.80 |
| Return on Investments | 8.70 |
| Profitability | |
| Gross Margin | 72.30 |
| EBIT Margin | 4.80 |
| Profit Margin | 4.10 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,439.31 | 1,315.57 | 2,843.45 | 16.31 |
Oil *
103.32
|
|
DOWN
141.38 |
DOWN
16.85 |
DOWN
27.54 |
DOWN
1.00 |
10 Yr
1.63%
SPDR Gold
151.97
|
|
-1.12%
|
-1.26%
|
-0.96%
|
-5.78%
|
Data delayed 20 minutes |
Connect with TheStreet